Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
- 6 Modeling Approaches That Make Complex Bioprocess Data Useful
- Building Trust In AI For Computerized System Validation
- A Gentler Cell Line Selection Method Using microRNA
- Controls For Retrieval-Augmented Generation In GxP
- Implementing AI Solutions In GMP While Managing Risk
GUEST COLUMNISTS
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
6 Modeling Approaches That Make Complex Bioprocess Data Useful
AI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
-
Building Trust In AI For Computerized System Validation
Using AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
-
Controls For Retrieval-Augmented Generation In GxP
Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
-
Implementing AI Solutions In GMP While Managing Risk
When using artificial intelligence in GMP settings, risk management extends far beyond validation. This discussion explores moving AI solutions out of the pilot phase.
BIOSIMILAR WHITE PAPERS
-
Innovation In Filtration
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
-
Process Analytical Technology In The ADC Bioconjugation Process4/23/2025
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators4/28/2025
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Reliability In Bioprocessing Is Your Competitive Advantage9/11/2026
Equipment reliability is a prerequisite for realizing value from digital transformation, automation, and data-driven initiatives in bioprocess manufacturing.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
How Lipid Nanoparticles Enable Next-Gen Delivery10/20/2025
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
BIOSIMILAR APP NOTES & CASE STUDIES
- Performance Of Mobius® Bag Assemblies With Ultimus® Film In Truck Shipping Simulation Test
- Optimized Product Recovery Using The Drug Product Filtration System
- Replicate Bioscience And Cytiva Collaborate To Deliver srRNA-LNP Vaccines
- Process Intensification Through Downstream Connectivity
- Scale-Up Of AAV Production In Fixed-Bed Bioreactors
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Orion Pharma Announces Agreement With Qilu Pharma Europe For Pembrolizumab Biosimilar For European Market
- Formycon Optimizes Biosimilar Development With AI-Powered Technologies: Digital Solutions Enhance Development Efficiency As Part Of The FYB4GROWTH Strategy
- FDA Approves Additional U.S. Manufacturing Capacity For SIMLANDI®, Alvotech's Biosimilar To Humira®
- OMLYCLO® (omalizumab-igec), The First And Only FDA-Approved Interchangeable Biosimilar To XOLAIR®, Now Commercially Available In The U.S.
- The Biosimilars Forum Commends Governor Newsom For Signing Landmark Biosimilars Legislation Into Law
- Samsung Bioepis And Teva Expand Strategic Partnership To Advance Up To Six Potential Biosimilar Candidates
- Fresenius Completes Acquisition Of mAbxience, Creating A Stronger Platform For Future Portfolio Expansion
NEWSLETTER ARCHIVE
- 10.08.26 -- Building Trust In AI For Computerized System Validation
- 10.01.26 -- Faster Paths To Biosimilar Equivalence
- 09.24.26 -- Navigating The Regulatory Space To Biosimilar Approval
- 09.17.26 -- Your Collaborator: mAb Productivity And Robustness
- 09.17.26 -- A Much-Improved Approach For Managing Safety Risks